Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI). Objectives: To evaluate the in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborb...
Guardado en:
Autores principales: | Helio S. Sader, Mariana Castanheira, Leonard R. Duncan, Rodrigo E. Mendes |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bf9c27dc44894de6a4e64077bcd0288a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Treatment of UTIs Due to <i>Klebsiella pneumoniae</i> Carbapenemase-Producers: How to Use New Antibiotic Drugs? A Narrative Review
por: Caroline Chapelle, et al.
Publicado: (2021) -
Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections
por: Helen L. Zhang, et al.
Publicado: (2021) -
Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015–2018
por: Michael A. Pfaller, et al.
Publicado: (2021) -
Bacterial membrane vesicles from Acinetobacter baumannii induced by ceftazidime are more virulent than those induced by imipenem
por: Chun-Hsiang Chiu, et al.
Publicado: (2020) -
Analyses of a Ceftazidime-Avibactam-Resistant <italic toggle="yes">Citrobacter freundii</italic> Isolate Carrying <italic toggle="yes">bla</italic><sub>KPC-2</sub> Reveals a Heterogenous Population and Reversible Genotype
por: Mariana Castanheira, et al.
Publicado: (2018)